SlideShare a Scribd company logo
Monica Mukherjee, MD, MPH, FACC, FASE
Assistant Professor of Medicine
Johns Hopkins University Division of Cardiology
Baltimore, Maryland
JNC 8 Updates on Hypertension
Email: mmukher2@jhmi.edu
Disclosures
• None
6 December 2016
Introduction
• Hypertension affects 29% US adult population
– Estimated 72 million people, with a prevalence of >65% in persons older
than 60 yrs, 1 in 3 adults
• Hypertension disproportionately affects the African American
community with over 45% AA males and 46% AA females affected
by high blood pressure compared to a national rate of 33%.
• Attributable risk factor in 41% of all CVD deaths from MI, heart
failure, and stroke
• HTN in middle age is known to increase the risk of chronic kidney
disease (CKD) and dementia in later life
6 December 2016 Nwankwo T, et al. Natl Center Health Stat. 2013;133:1–8
Gottesman R, et al. JAMA Neurol. 2014;71:1218–27
Introduction
• Graded relationship between increasing BP and risk of
CVD
– Increase in BP 20 mmHg systolic or 10 mmHg diastolic
associated with a doubling of the risk of CVD death, regardless
of age
• Despite increasing BP recognition and improvement in
control are improving, nearly half of the hypertensive
population remains suboptimally controlled
6 December 2016 Lewington S, et al. Lancet. 2002;360:1903–13
Many Americans are living with high
blood pressure that is not controlled
5
From 2009 to 2012 among US adults with HBP
Our Goal for
Better Control
AHA 2015 Statistical Update
Slide courtesy of the American Heart Association
JNC 8 Recommendations
• JNC7 published in 2003, IOM called for updated
guidelines in 2011 aimed at answering 3 major
questions:
– Does initiating antihypertensive treatment at specific BP
thresholds improve health outcomes?
– Does treatment with antihypertensive therapy to a specific BP
goal improve health outcomes?
– Are there differences in benefit/harm between antihypertensive
drugs or drug classes on specific health outcomes?
6 December 2016 Kovell LC et al. J Am Heart Assoc. 2015;4(12): e002315
James PA et al. JAMA. 2014;311:507–20
JNC 8 Recommendation 1
• In the general population ≥ 60 yrs, initiate pharmacologic
treatment at SBP ≥150 mmHg or DBP ≥90 mmHg and treat
to a goal SBP <150 mmHg and DBP <90 mmHg
• JNC 8 BP target of <150/90 mmHg is recommended for
those older than 60 yrs, evidence for this target is strongest
for those >80 yrs
– Hypertension in the Very Elderly Trial: benefit to treating patients
>80 yrs to an average SBP of 144 mmHg
– 39% reduction in fatal strokes, 21% reduction in death from any
cause, and 64% reduction in HF
– Frail adults >80 yrs were excluded from the trial
6 December 2016 Kovell LC et al. J Am Heart Assoc. 2015;4(12): e002315.
Beckett NS et al. N Engl J Med. 2008;359:1887-98
JNC 8 Recommendation 1
• SPRINT designed to look for a benefit of intensive BP treatment in
those at risk for developing heart failure or CVD
– Randomized 9361 nondiabetic adults ≥50 yrs with no prior stroke to a standard
group with target SBP <140 mmHg and an intensive group with target SBP
<120 mmHg
– Average age of 68 yrs and Framingham 10-year CVD risk 20%
• Significantly reduced relative rates of CVD-related death
(43%, p=0.005) and events (25%, P<0.001)
• Reduction in CVD events came at the cost of higher rates of
hypotension, acute kidney injury, syncope, and electrolyte
disturbances
• Results from SPRINT contradict the recommendations of JNC8 and
may support even lower SBP targets for the consideration of the new
AHA/ACC guideline committee
6 December 2016 Ambrosius WT et al. Clin Trials. 2014;11:532–546
JNC 8 Recommendation 2
• In all persons <60 yrs or >18 yrs (and either those
younger or older than 60 yrs with either DM or CKD),
initiate pharmacologic treatment to lower SBP ≥140 or
DBP ≥90 mmHg and treat to a goal BP of
<140/90 mmHg
• Recommendation for target BP in DM by most
professional societies is <140/90 mmHg, although
ESH/ESC recommend a DBP target of <85 mmHg
– More support can be found for DBP versus SBP goals among
younger adults with HTN and DM
6 December 2016 Kovell LC et al. J Am Heart Assoc. 2015;4(12): e002315.
Hansson L et a. Lancet 2008;351:1755–1762
Summary Recommendations
6 December 2016 Kovell LC et al. J Am Heart Assoc. 2015;4(12): e002315
Guidelines for Referral
Visit and Clinical Status Blood Pressure Recommendations
Hypertensive urgency or emergency ≧ 210 and/or
≧120 mmHg
1. Recheck BP after 5 minutes
2. Abort any planned procedure, call 911
3. Provide referral note with details of BP
Single-visit dental hygienist’s
reading for a patient/client with a
history of risk factors (prior MI,
angina, recurrent stroke, DM, renal
disease)
180-209 and/or
110/119 mmHg
1. Recheck BP after 5 minutes
2. Abort any planned procedure, call 911
3. Provide referral note with details of BP
4. Refer the patient/client for a medical
consultation
Single-visit dental hygienist’s
reading for a patient/client with a
history of risk factors (prior MI,
angina, recurrent stroke, DM, renal
disease)
1. Re-check BP after 5 minutes
2. Perform only non-invasive dental
hygiene care; avoid invasive
procedures
3. Give the patient/client a written note of
all the BP readings
4. Refer the patient/client for a medical
consultation
6 December 2016 Adapted from: Zahedi S. Oral Health 2012-02-01.
Guidelines for Referral
Visit and Clinical Status Blood Pressure Recommendations
Single-visit dental hygienist’s reading
for a patient/client with a history of
risk factors (prior MI, angina,
recurrent stroke, DM, renal disease)
160-179 and/or
100-109 mmHg
1. Recheck BP after 5 minutes
2. Perform only non-invasive dental
hygiene care; avoid invasive
procedures
3. Give the patient/client a written note of
all the BP readings
4. Refer the patient/client for a medical
consultation
Single-visit dental hygienist’s reading
for a patient/client with a history of
risk factors (prior MI, angina,
recurrent stroke, DM, renal disease)
130-159 and/or
80-99 mmHg
1. Re-check BP after 5 minutes
2. Perform only non-invasive dental
hygiene care; avoid invasive
procedures
3. Give the patient/client a written note of
all the BP readings
4. Refer the patient/client for a medical
consultation
6 December 2016 Adapted from: Zahedi S. Oral Health 2012-02-01.
Guidelines for Referral
Visit and Clinical Status Blood Pressure Recommendations
Single-visit dental hygienist’s reading
for a patient/client with a history of
risk factors (prior MI, angina,
recurrent stroke, DM, renal disease)
or who is receiving anti-hypertensive
medication
<130 and/or 80
mmHg
1. Proceed with dental hygiene care and
procedures as required
6 December 2016 Adapted from: Zahedi S. Oral Health 2012-02-01.
Blood Pressure Management
American Heart Association Programs
AHA is working toward that goal here in Maryland by
encouraging participation in these two blood pressure
management programs.
Target: BP
§ AHA/AMA call to action
§ Clinical resources for improving HBP
§ Recognition
Check. Change. Control.®
§ Individual self-management program
§ Offered through key partners
14
Slide courtesy of the American Heart Association
Blood Pressure Management
What is Target: BP?
15
A call to action motivating medical practices,
practitioners and health services organizations to
prioritize blood pressure control
Recognition for healthcare providers who attain high
levels of blood pressure control in their patient
populations, particularly those who achieve 70, 80
percent or higher control
A source for tools and assets for healthcare providers
to use in practice, including the AHA/ACC/CDC
Hypertension Treatment Algorithm and the AMA’s
M.A.P. Checklist
ü
ü
ü
Slide courtesy of the American Heart Association
Blood Pressure Management
What is Check. Change. Control.®?
16
Developed to support hypertension management among
the adult population, Check. Change. Control.® engages
participants, emphasizing 3 important aspects of
managing hypertension:
1.Checking for high blood pressure and symptoms;
2.Changing lifestyle and seeking treatment;
3.Controlling hypertension by taking preventative
measures.
Slide courtesy of the American Heart Association
Additional Resources
AHA Go Red for Women Campaign
https://www.goredforwomen.org
Johns Hopkins Women's Cardiovascular Health Center
Monica Mukherjee, MD, MPH, mmukher2@jhmi.edu
American Heart Association, Maryland
Danelle Buchman, Senior Community Health Director, danelle.buchman@heart.org
17
SUPPLEMENTAL SLIDES
Special Consideration
6 December 2016
Special Consideration: Diabetes
• Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial compared 2 SBP targets in diabetic
patients, <140 or <120 mmHg
– 4.7 yrs follow-up, the primary outcome of nonfatal MI, stroke, or
CVD death was not significantly different between the 2 groups
– Total stroke rate in intensive arm was reduced by 41% (p=0.01)
• Based on these studies, achieving a lower BP goal in
people with diabetes appears to be more consistently
associated with a lower risk of stroke than MI
– Support a target SBP <140 mmHg and DBP <85 mmHg in DM
6 December 2016 ACCORD Study Group. N Engl J Med. 2010;362:1575–85.
Special Consideration: Diabetes
• Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial compared 2 SBP targets in diabetic
patients, <140 or <120 mmHg
– 4.7 yrs follow-up, the primary outcome of nonfatal MI, stroke, or
CVD death was not significantly different between the 2 groups
– Total stroke rate in intensive arm was reduced by 41% (p=0.01)
• Based on these studies, achieving a lower BP goal in
people with diabetes appears to be more consistently
associated with a lower risk of stroke than MI
– Support a target SBP <140 mmHg and DBP <85 mmHg in DM
6 December 2016 ACCORD Study Group. N Engl J Med. 2010;362:1575–85.
Special Consideration: CKD
• BP targets in CKD were also increased from <130/80 to
<140/90 mmHg between the JNC 7 à JNC 8
• Important distinction between CKD based on proteinuria
status, with a lower BP goal of <130/80 to 90 mmHg for
those with proteinuria detectable on urinanalysis
• Given that the baseline risk of the patient appears to
influence the outcomes of BP treatment, a lower BP goal
of <130/80 mmHg may be recommended for those with
>300 mg/d proteinuria
6 December 2016 Flack JM. Hypertension 2010;56:780-800.
Weber MA. J Hypertens. 2014;32:3–15.
Special Consideration:
Secondary Prevention of CVD
• AHA, ACC, ASH, ESC endorse a goal of
<140/90 mmHg for those with HTN and CVD with an
optional target of <130/80 mmHg for those with CVD
and previous MI, stroke/TIA, carotid artery disease,
peripheral arterial disease, or abdominal aortic
aneurysm
6 December 2016 Rosendorff C. Circulation 2007;115:2761-88.
JNC 8 Recommendation 6-9
• In the general nonblack population, including those with DM,
initial antihypertensive treatment should include a
thiazide-type diuretic, CCB, ACEI, or ARB
• In the general black population, including those with
diabetes, initial antihypertensive treatment should include a
thiazide-type diuretic or CCB
– In the black population with HTN (no DM or CKD), CCBs and
thiazide diuretics generally tend to be favored as initial therapy
over renin-angiotensin system blockers based on subgroup
analysis from ALLHAT
– If a black patient has coexisting CKD and albuminuria, initial
treatment should be an ACEI or ARB
6 December 2016 James PA et al. JAMA. 2014;311:507–20
ALLHAT Investigators. JAMA. 2002;288:2981–97
JNC 8 Recommendation 6-9
• In the population aged ≥18 yrs with CKD, initial (or
add-on) antihypertensive treatment should include an
ACEI or ARB to improve kidney outcomes
– Baseline risk and degree of proteinuria important in guiding
intensiveness of antihypertensive therapies
• While JNC 8 has the same treatment recommendations
for people with or without diabetes, most other societies
suggest that only ACEIs or ARBs should be first-line
treatment for patients with diabetes
6 December 2016 Kovell LC et al. J Am Heart Assoc. 2015;4(12): e002315
James PA et al. JAMA. 2014;311:507–20

More Related Content

Similar to UpdatesOnHypertension (1).pdf

Bp targets 2014-2015
Bp targets 2014-2015Bp targets 2014-2015
Bp targets 2014-2015
magdy elmasry
 
Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...
Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...
Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...
Vinh Pham Nguyen
 
Heartbeat 167 October 2015 HBP
Heartbeat 167 October 2015 HBPHeartbeat 167 October 2015 HBP
Heartbeat 167 October 2015 HBP
Mario L Maiese
 
Sarva sprint trial
Sarva sprint trialSarva sprint trial
Sarva sprint trial
Saravanan Saktthivelu
 
JNC-8.ppt
JNC-8.pptJNC-8.ppt
JNC-8.ppt
dtettam1
 
JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013
JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013
JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013
Praveen Nagula
 
Hypertension guidelines
Hypertension guidelinesHypertension guidelines
Hypertension guidelines
Sachin Shende
 
Update in hypertension management
Update in hypertension managementUpdate in hypertension management
Update in hypertension management
Tarek Khalil
 
New 2017 aha acc hypertension guidelines
New 2017 aha acc hypertension guidelinesNew 2017 aha acc hypertension guidelines
New 2017 aha acc hypertension guidelines
gisa_legal
 
Challenge in management of hypertension
Challenge in management  of hypertensionChallenge in management  of hypertension
Challenge in management of hypertension
SolidaSakhan
 
Jnc 8
Jnc 8Jnc 8
Hypertension guidelines comparison.pptx
Hypertension guidelines comparison.pptxHypertension guidelines comparison.pptx
Hypertension guidelines comparison.pptx
desktoppc
 
Hypertension redefined
Hypertension redefinedHypertension redefined
Hypertension redefined
vinay tuteja
 
Management of hypertension
Management of hypertensionManagement of hypertension
Management of hypertension
Kerolus Shehata
 
comparison of hypertension
comparison  of hypertensioncomparison  of hypertension
comparison of hypertension
SoM
 
Jnc8 2014
Jnc8 2014Jnc8 2014
Jnc8 2014
Julio León
 
JNC8 2014
JNC8 2014JNC8 2014
JNC8 2014
sandoriver
 
Eighth Joint National Committee (JNC 8) - Blood Pressure in Adults
Eighth Joint National Committee (JNC 8) - Blood Pressure in AdultsEighth Joint National Committee (JNC 8) - Blood Pressure in Adults
Eighth Joint National Committee (JNC 8) - Blood Pressure in Adults
Sandru Acevedo MD
 
Jnc 8 guidelines for management of high blood pressure: Lets compare with JNC 7
Jnc 8 guidelines for management of high blood pressure: Lets compare with JNC 7Jnc 8 guidelines for management of high blood pressure: Lets compare with JNC 7
Jnc 8 guidelines for management of high blood pressure: Lets compare with JNC 7
Dr. Afzal Haq Asif
 
Guia de manejo de hta adultos 2014
Guia de manejo de hta adultos 2014Guia de manejo de hta adultos 2014
Guia de manejo de hta adultos 2014
Freddy Flores Malpartida
 

Similar to UpdatesOnHypertension (1).pdf (20)

Bp targets 2014-2015
Bp targets 2014-2015Bp targets 2014-2015
Bp targets 2014-2015
 
Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...
Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...
Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...
 
Heartbeat 167 October 2015 HBP
Heartbeat 167 October 2015 HBPHeartbeat 167 October 2015 HBP
Heartbeat 167 October 2015 HBP
 
Sarva sprint trial
Sarva sprint trialSarva sprint trial
Sarva sprint trial
 
JNC-8.ppt
JNC-8.pptJNC-8.ppt
JNC-8.ppt
 
JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013
JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013
JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013
 
Hypertension guidelines
Hypertension guidelinesHypertension guidelines
Hypertension guidelines
 
Update in hypertension management
Update in hypertension managementUpdate in hypertension management
Update in hypertension management
 
New 2017 aha acc hypertension guidelines
New 2017 aha acc hypertension guidelinesNew 2017 aha acc hypertension guidelines
New 2017 aha acc hypertension guidelines
 
Challenge in management of hypertension
Challenge in management  of hypertensionChallenge in management  of hypertension
Challenge in management of hypertension
 
Jnc 8
Jnc 8Jnc 8
Jnc 8
 
Hypertension guidelines comparison.pptx
Hypertension guidelines comparison.pptxHypertension guidelines comparison.pptx
Hypertension guidelines comparison.pptx
 
Hypertension redefined
Hypertension redefinedHypertension redefined
Hypertension redefined
 
Management of hypertension
Management of hypertensionManagement of hypertension
Management of hypertension
 
comparison of hypertension
comparison  of hypertensioncomparison  of hypertension
comparison of hypertension
 
Jnc8 2014
Jnc8 2014Jnc8 2014
Jnc8 2014
 
JNC8 2014
JNC8 2014JNC8 2014
JNC8 2014
 
Eighth Joint National Committee (JNC 8) - Blood Pressure in Adults
Eighth Joint National Committee (JNC 8) - Blood Pressure in AdultsEighth Joint National Committee (JNC 8) - Blood Pressure in Adults
Eighth Joint National Committee (JNC 8) - Blood Pressure in Adults
 
Jnc 8 guidelines for management of high blood pressure: Lets compare with JNC 7
Jnc 8 guidelines for management of high blood pressure: Lets compare with JNC 7Jnc 8 guidelines for management of high blood pressure: Lets compare with JNC 7
Jnc 8 guidelines for management of high blood pressure: Lets compare with JNC 7
 
Guia de manejo de hta adultos 2014
Guia de manejo de hta adultos 2014Guia de manejo de hta adultos 2014
Guia de manejo de hta adultos 2014
 

More from jiregnaetichadako

DRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdfDRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdf
jiregnaetichadako
 
anaemia-170224190304 (1).pdf
anaemia-170224190304 (1).pdfanaemia-170224190304 (1).pdf
anaemia-170224190304 (1).pdf
jiregnaetichadako
 
anemia-170709121059.pdf
anemia-170709121059.pdfanemia-170709121059.pdf
anemia-170709121059.pdf
jiregnaetichadako
 
Regression-Logistic-4.pdf
Regression-Logistic-4.pdfRegression-Logistic-4.pdf
Regression-Logistic-4.pdf
jiregnaetichadako
 
DRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdfDRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdf
jiregnaetichadako
 
2.pdf
2.pdf2.pdf
1.ppt
1.ppt1.ppt
hypertension-200501101309 (3).pdf
hypertension-200501101309 (3).pdfhypertension-200501101309 (3).pdf
hypertension-200501101309 (3).pdf
jiregnaetichadako
 
Hypertension-ppt (1).pptx
Hypertension-ppt (1).pptxHypertension-ppt (1).pptx
Hypertension-ppt (1).pptx
jiregnaetichadako
 
coronaryangiogram-140520060959-phpapp01.pdf
coronaryangiogram-140520060959-phpapp01.pdfcoronaryangiogram-140520060959-phpapp01.pdf
coronaryangiogram-140520060959-phpapp01.pdf
jiregnaetichadako
 
coronaryangiography-220330142539 (1).pdf
coronaryangiography-220330142539 (1).pdfcoronaryangiography-220330142539 (1).pdf
coronaryangiography-220330142539 (1).pdf
jiregnaetichadako
 
coronaryangiographymadhu-151130170912-lva1-app6892 (1).pdf
coronaryangiographymadhu-151130170912-lva1-app6892 (1).pdfcoronaryangiographymadhu-151130170912-lva1-app6892 (1).pdf
coronaryangiographymadhu-151130170912-lva1-app6892 (1).pdf
jiregnaetichadako
 
vascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdf
vascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdfvascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdf
vascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdf
jiregnaetichadako
 
NUTRITION 2105-LECTURE 6B.ppt
NUTRITION 2105-LECTURE 6B.pptNUTRITION 2105-LECTURE 6B.ppt
NUTRITION 2105-LECTURE 6B.ppt
jiregnaetichadako
 
heartfailurelecture-140122113443-phpapp02 (1).pdf
heartfailurelecture-140122113443-phpapp02 (1).pdfheartfailurelecture-140122113443-phpapp02 (1).pdf
heartfailurelecture-140122113443-phpapp02 (1).pdf
jiregnaetichadako
 
lecture_5_drug_acting_on_the_heart (1).ppt
lecture_5_drug_acting_on_the_heart (1).pptlecture_5_drug_acting_on_the_heart (1).ppt
lecture_5_drug_acting_on_the_heart (1).ppt
jiregnaetichadako
 
myocardialinfractionramesh-170504133703 (1).pdf
myocardialinfractionramesh-170504133703 (1).pdfmyocardialinfractionramesh-170504133703 (1).pdf
myocardialinfractionramesh-170504133703 (1).pdf
jiregnaetichadako
 
myocardialinfarction-150223043527-conversion-gate02 (1).pdf
myocardialinfarction-150223043527-conversion-gate02 (1).pdfmyocardialinfarction-150223043527-conversion-gate02 (1).pdf
myocardialinfarction-150223043527-conversion-gate02 (1).pdf
jiregnaetichadako
 
ecg_systemic_approach_12-lead_compressed.pdf
ecg_systemic_approach_12-lead_compressed.pdfecg_systemic_approach_12-lead_compressed.pdf
ecg_systemic_approach_12-lead_compressed.pdf
jiregnaetichadako
 
Common_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptx
Common_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptxCommon_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptx
Common_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptx
jiregnaetichadako
 

More from jiregnaetichadako (20)

DRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdfDRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdf
 
anaemia-170224190304 (1).pdf
anaemia-170224190304 (1).pdfanaemia-170224190304 (1).pdf
anaemia-170224190304 (1).pdf
 
anemia-170709121059.pdf
anemia-170709121059.pdfanemia-170709121059.pdf
anemia-170709121059.pdf
 
Regression-Logistic-4.pdf
Regression-Logistic-4.pdfRegression-Logistic-4.pdf
Regression-Logistic-4.pdf
 
DRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdfDRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdf
 
2.pdf
2.pdf2.pdf
2.pdf
 
1.ppt
1.ppt1.ppt
1.ppt
 
hypertension-200501101309 (3).pdf
hypertension-200501101309 (3).pdfhypertension-200501101309 (3).pdf
hypertension-200501101309 (3).pdf
 
Hypertension-ppt (1).pptx
Hypertension-ppt (1).pptxHypertension-ppt (1).pptx
Hypertension-ppt (1).pptx
 
coronaryangiogram-140520060959-phpapp01.pdf
coronaryangiogram-140520060959-phpapp01.pdfcoronaryangiogram-140520060959-phpapp01.pdf
coronaryangiogram-140520060959-phpapp01.pdf
 
coronaryangiography-220330142539 (1).pdf
coronaryangiography-220330142539 (1).pdfcoronaryangiography-220330142539 (1).pdf
coronaryangiography-220330142539 (1).pdf
 
coronaryangiographymadhu-151130170912-lva1-app6892 (1).pdf
coronaryangiographymadhu-151130170912-lva1-app6892 (1).pdfcoronaryangiographymadhu-151130170912-lva1-app6892 (1).pdf
coronaryangiographymadhu-151130170912-lva1-app6892 (1).pdf
 
vascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdf
vascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdfvascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdf
vascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdf
 
NUTRITION 2105-LECTURE 6B.ppt
NUTRITION 2105-LECTURE 6B.pptNUTRITION 2105-LECTURE 6B.ppt
NUTRITION 2105-LECTURE 6B.ppt
 
heartfailurelecture-140122113443-phpapp02 (1).pdf
heartfailurelecture-140122113443-phpapp02 (1).pdfheartfailurelecture-140122113443-phpapp02 (1).pdf
heartfailurelecture-140122113443-phpapp02 (1).pdf
 
lecture_5_drug_acting_on_the_heart (1).ppt
lecture_5_drug_acting_on_the_heart (1).pptlecture_5_drug_acting_on_the_heart (1).ppt
lecture_5_drug_acting_on_the_heart (1).ppt
 
myocardialinfractionramesh-170504133703 (1).pdf
myocardialinfractionramesh-170504133703 (1).pdfmyocardialinfractionramesh-170504133703 (1).pdf
myocardialinfractionramesh-170504133703 (1).pdf
 
myocardialinfarction-150223043527-conversion-gate02 (1).pdf
myocardialinfarction-150223043527-conversion-gate02 (1).pdfmyocardialinfarction-150223043527-conversion-gate02 (1).pdf
myocardialinfarction-150223043527-conversion-gate02 (1).pdf
 
ecg_systemic_approach_12-lead_compressed.pdf
ecg_systemic_approach_12-lead_compressed.pdfecg_systemic_approach_12-lead_compressed.pdf
ecg_systemic_approach_12-lead_compressed.pdf
 
Common_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptx
Common_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptxCommon_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptx
Common_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptx
 

Recently uploaded

K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Hiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital Powai News [Read Now].pdfHiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital Powai News [Read Now].pdf
Dr. Sujit Chatterjee CEO Hiranandani Hospital
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
BrissaOrtiz3
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
DIVYANSHU740006
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
All info about Diabetes and how to control it.
 All info about Diabetes and how to control it. All info about Diabetes and how to control it.
All info about Diabetes and how to control it.
Gokuldas Hospital
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 

Recently uploaded (20)

K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Hiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital Powai News [Read Now].pdfHiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital Powai News [Read Now].pdf
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
All info about Diabetes and how to control it.
 All info about Diabetes and how to control it. All info about Diabetes and how to control it.
All info about Diabetes and how to control it.
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 

UpdatesOnHypertension (1).pdf

  • 1. Monica Mukherjee, MD, MPH, FACC, FASE Assistant Professor of Medicine Johns Hopkins University Division of Cardiology Baltimore, Maryland JNC 8 Updates on Hypertension Email: mmukher2@jhmi.edu
  • 3. Introduction • Hypertension affects 29% US adult population – Estimated 72 million people, with a prevalence of >65% in persons older than 60 yrs, 1 in 3 adults • Hypertension disproportionately affects the African American community with over 45% AA males and 46% AA females affected by high blood pressure compared to a national rate of 33%. • Attributable risk factor in 41% of all CVD deaths from MI, heart failure, and stroke • HTN in middle age is known to increase the risk of chronic kidney disease (CKD) and dementia in later life 6 December 2016 Nwankwo T, et al. Natl Center Health Stat. 2013;133:1–8 Gottesman R, et al. JAMA Neurol. 2014;71:1218–27
  • 4. Introduction • Graded relationship between increasing BP and risk of CVD – Increase in BP 20 mmHg systolic or 10 mmHg diastolic associated with a doubling of the risk of CVD death, regardless of age • Despite increasing BP recognition and improvement in control are improving, nearly half of the hypertensive population remains suboptimally controlled 6 December 2016 Lewington S, et al. Lancet. 2002;360:1903–13
  • 5. Many Americans are living with high blood pressure that is not controlled 5 From 2009 to 2012 among US adults with HBP Our Goal for Better Control AHA 2015 Statistical Update Slide courtesy of the American Heart Association
  • 6. JNC 8 Recommendations • JNC7 published in 2003, IOM called for updated guidelines in 2011 aimed at answering 3 major questions: – Does initiating antihypertensive treatment at specific BP thresholds improve health outcomes? – Does treatment with antihypertensive therapy to a specific BP goal improve health outcomes? – Are there differences in benefit/harm between antihypertensive drugs or drug classes on specific health outcomes? 6 December 2016 Kovell LC et al. J Am Heart Assoc. 2015;4(12): e002315 James PA et al. JAMA. 2014;311:507–20
  • 7. JNC 8 Recommendation 1 • In the general population ≥ 60 yrs, initiate pharmacologic treatment at SBP ≥150 mmHg or DBP ≥90 mmHg and treat to a goal SBP <150 mmHg and DBP <90 mmHg • JNC 8 BP target of <150/90 mmHg is recommended for those older than 60 yrs, evidence for this target is strongest for those >80 yrs – Hypertension in the Very Elderly Trial: benefit to treating patients >80 yrs to an average SBP of 144 mmHg – 39% reduction in fatal strokes, 21% reduction in death from any cause, and 64% reduction in HF – Frail adults >80 yrs were excluded from the trial 6 December 2016 Kovell LC et al. J Am Heart Assoc. 2015;4(12): e002315. Beckett NS et al. N Engl J Med. 2008;359:1887-98
  • 8. JNC 8 Recommendation 1 • SPRINT designed to look for a benefit of intensive BP treatment in those at risk for developing heart failure or CVD – Randomized 9361 nondiabetic adults ≥50 yrs with no prior stroke to a standard group with target SBP <140 mmHg and an intensive group with target SBP <120 mmHg – Average age of 68 yrs and Framingham 10-year CVD risk 20% • Significantly reduced relative rates of CVD-related death (43%, p=0.005) and events (25%, P<0.001) • Reduction in CVD events came at the cost of higher rates of hypotension, acute kidney injury, syncope, and electrolyte disturbances • Results from SPRINT contradict the recommendations of JNC8 and may support even lower SBP targets for the consideration of the new AHA/ACC guideline committee 6 December 2016 Ambrosius WT et al. Clin Trials. 2014;11:532–546
  • 9. JNC 8 Recommendation 2 • In all persons <60 yrs or >18 yrs (and either those younger or older than 60 yrs with either DM or CKD), initiate pharmacologic treatment to lower SBP ≥140 or DBP ≥90 mmHg and treat to a goal BP of <140/90 mmHg • Recommendation for target BP in DM by most professional societies is <140/90 mmHg, although ESH/ESC recommend a DBP target of <85 mmHg – More support can be found for DBP versus SBP goals among younger adults with HTN and DM 6 December 2016 Kovell LC et al. J Am Heart Assoc. 2015;4(12): e002315. Hansson L et a. Lancet 2008;351:1755–1762
  • 10. Summary Recommendations 6 December 2016 Kovell LC et al. J Am Heart Assoc. 2015;4(12): e002315
  • 11. Guidelines for Referral Visit and Clinical Status Blood Pressure Recommendations Hypertensive urgency or emergency ≧ 210 and/or ≧120 mmHg 1. Recheck BP after 5 minutes 2. Abort any planned procedure, call 911 3. Provide referral note with details of BP Single-visit dental hygienist’s reading for a patient/client with a history of risk factors (prior MI, angina, recurrent stroke, DM, renal disease) 180-209 and/or 110/119 mmHg 1. Recheck BP after 5 minutes 2. Abort any planned procedure, call 911 3. Provide referral note with details of BP 4. Refer the patient/client for a medical consultation Single-visit dental hygienist’s reading for a patient/client with a history of risk factors (prior MI, angina, recurrent stroke, DM, renal disease) 1. Re-check BP after 5 minutes 2. Perform only non-invasive dental hygiene care; avoid invasive procedures 3. Give the patient/client a written note of all the BP readings 4. Refer the patient/client for a medical consultation 6 December 2016 Adapted from: Zahedi S. Oral Health 2012-02-01.
  • 12. Guidelines for Referral Visit and Clinical Status Blood Pressure Recommendations Single-visit dental hygienist’s reading for a patient/client with a history of risk factors (prior MI, angina, recurrent stroke, DM, renal disease) 160-179 and/or 100-109 mmHg 1. Recheck BP after 5 minutes 2. Perform only non-invasive dental hygiene care; avoid invasive procedures 3. Give the patient/client a written note of all the BP readings 4. Refer the patient/client for a medical consultation Single-visit dental hygienist’s reading for a patient/client with a history of risk factors (prior MI, angina, recurrent stroke, DM, renal disease) 130-159 and/or 80-99 mmHg 1. Re-check BP after 5 minutes 2. Perform only non-invasive dental hygiene care; avoid invasive procedures 3. Give the patient/client a written note of all the BP readings 4. Refer the patient/client for a medical consultation 6 December 2016 Adapted from: Zahedi S. Oral Health 2012-02-01.
  • 13. Guidelines for Referral Visit and Clinical Status Blood Pressure Recommendations Single-visit dental hygienist’s reading for a patient/client with a history of risk factors (prior MI, angina, recurrent stroke, DM, renal disease) or who is receiving anti-hypertensive medication <130 and/or 80 mmHg 1. Proceed with dental hygiene care and procedures as required 6 December 2016 Adapted from: Zahedi S. Oral Health 2012-02-01.
  • 14. Blood Pressure Management American Heart Association Programs AHA is working toward that goal here in Maryland by encouraging participation in these two blood pressure management programs. Target: BP § AHA/AMA call to action § Clinical resources for improving HBP § Recognition Check. Change. Control.® § Individual self-management program § Offered through key partners 14 Slide courtesy of the American Heart Association
  • 15. Blood Pressure Management What is Target: BP? 15 A call to action motivating medical practices, practitioners and health services organizations to prioritize blood pressure control Recognition for healthcare providers who attain high levels of blood pressure control in their patient populations, particularly those who achieve 70, 80 percent or higher control A source for tools and assets for healthcare providers to use in practice, including the AHA/ACC/CDC Hypertension Treatment Algorithm and the AMA’s M.A.P. Checklist ü ü ü Slide courtesy of the American Heart Association
  • 16. Blood Pressure Management What is Check. Change. Control.®? 16 Developed to support hypertension management among the adult population, Check. Change. Control.® engages participants, emphasizing 3 important aspects of managing hypertension: 1.Checking for high blood pressure and symptoms; 2.Changing lifestyle and seeking treatment; 3.Controlling hypertension by taking preventative measures. Slide courtesy of the American Heart Association
  • 17. Additional Resources AHA Go Red for Women Campaign https://www.goredforwomen.org Johns Hopkins Women's Cardiovascular Health Center Monica Mukherjee, MD, MPH, mmukher2@jhmi.edu American Heart Association, Maryland Danelle Buchman, Senior Community Health Director, danelle.buchman@heart.org 17
  • 19. Special Consideration: Diabetes • Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial compared 2 SBP targets in diabetic patients, <140 or <120 mmHg – 4.7 yrs follow-up, the primary outcome of nonfatal MI, stroke, or CVD death was not significantly different between the 2 groups – Total stroke rate in intensive arm was reduced by 41% (p=0.01) • Based on these studies, achieving a lower BP goal in people with diabetes appears to be more consistently associated with a lower risk of stroke than MI – Support a target SBP <140 mmHg and DBP <85 mmHg in DM 6 December 2016 ACCORD Study Group. N Engl J Med. 2010;362:1575–85.
  • 20. Special Consideration: Diabetes • Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial compared 2 SBP targets in diabetic patients, <140 or <120 mmHg – 4.7 yrs follow-up, the primary outcome of nonfatal MI, stroke, or CVD death was not significantly different between the 2 groups – Total stroke rate in intensive arm was reduced by 41% (p=0.01) • Based on these studies, achieving a lower BP goal in people with diabetes appears to be more consistently associated with a lower risk of stroke than MI – Support a target SBP <140 mmHg and DBP <85 mmHg in DM 6 December 2016 ACCORD Study Group. N Engl J Med. 2010;362:1575–85.
  • 21. Special Consideration: CKD • BP targets in CKD were also increased from <130/80 to <140/90 mmHg between the JNC 7 à JNC 8 • Important distinction between CKD based on proteinuria status, with a lower BP goal of <130/80 to 90 mmHg for those with proteinuria detectable on urinanalysis • Given that the baseline risk of the patient appears to influence the outcomes of BP treatment, a lower BP goal of <130/80 mmHg may be recommended for those with >300 mg/d proteinuria 6 December 2016 Flack JM. Hypertension 2010;56:780-800. Weber MA. J Hypertens. 2014;32:3–15.
  • 22. Special Consideration: Secondary Prevention of CVD • AHA, ACC, ASH, ESC endorse a goal of <140/90 mmHg for those with HTN and CVD with an optional target of <130/80 mmHg for those with CVD and previous MI, stroke/TIA, carotid artery disease, peripheral arterial disease, or abdominal aortic aneurysm 6 December 2016 Rosendorff C. Circulation 2007;115:2761-88.
  • 23. JNC 8 Recommendation 6-9 • In the general nonblack population, including those with DM, initial antihypertensive treatment should include a thiazide-type diuretic, CCB, ACEI, or ARB • In the general black population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic or CCB – In the black population with HTN (no DM or CKD), CCBs and thiazide diuretics generally tend to be favored as initial therapy over renin-angiotensin system blockers based on subgroup analysis from ALLHAT – If a black patient has coexisting CKD and albuminuria, initial treatment should be an ACEI or ARB 6 December 2016 James PA et al. JAMA. 2014;311:507–20 ALLHAT Investigators. JAMA. 2002;288:2981–97
  • 24. JNC 8 Recommendation 6-9 • In the population aged ≥18 yrs with CKD, initial (or add-on) antihypertensive treatment should include an ACEI or ARB to improve kidney outcomes – Baseline risk and degree of proteinuria important in guiding intensiveness of antihypertensive therapies • While JNC 8 has the same treatment recommendations for people with or without diabetes, most other societies suggest that only ACEIs or ARBs should be first-line treatment for patients with diabetes 6 December 2016 Kovell LC et al. J Am Heart Assoc. 2015;4(12): e002315 James PA et al. JAMA. 2014;311:507–20